Allergan Sues Again To Block Generic Latisse

Law360, New York (August 18, 2011, 7:03 PM EDT) -- Allergan Inc. filed a patent infringement suit against Hi-Tech Pharmacal Co. Inc. in North Carolina on Wednesday in its latest effort to block a generic version of the eyelash growth treatment Latisse.

Allergan and Duke University claim that Hi-Tech's abbreviated new drug application infringes three patents in seeking permission to manufacture bimatoprost ophthalmic solution. The drug is marketed as Latisse, which was released in December 2008 as a treatment for hypotrichosis of the eyelashes and has become popular with consumers desiring longer or thicker lashes....
To view the full article, register now.